Tamsulosin, a selective α_1c‐adrenoceptor* antagonist: a randomized, controlled trial in patients with benign prostatic ‘obstruction’ (symptomatic BPH)

Abstract

Tamsulosin 0.4 mg once daily is safe, well tolerated and clinically effective in improving symptoms and urinary flow rate in patients with symptomatic BPH.

α1-Adrenoceptor selectivity and the treatment of benign prostatic hyperplasia and lower urinary tract symptoms

“…(1996) 65 Fawzy et al (1995) 59 Gillenwater et al (1995) ) 107 Abrams et al (1995) 61 Chapple et al (1996) 108 Lepor et al (1998) 109 Enhanced spinal re¯exes are also present in patients with obstruction and storage symptoms, as demonstrated by the ice-water test that triggers a C ®bre, capsaicinsensitive spinal micturition re¯ex. This re¯ex, which is normally present only in the ®rst few months of life, reoccurs in patients with suprasacral spinal injuries or upper motor neurone disease.…”

Alpha–1–adrenoceptor blockade in the treatment of benign prostatic hyperplasia

“…Therefore, the low placebo effect in this study produced an attributable drug effect on peak¯ow rate of 24%; this is markedly higher than that reported in the other four tamsulosin trials. 45,49,55,58 There is con¯icting evidence as to whether tamsulosin 0.4 and 0.8 mg produce different magnitudes of symptom relief. While the 0.4 mg dose produced a 9 ± 14% improvement over placebo in symptom score in four studies, 45,46,49,55 in one study the 0.8 mg produced a 20% improvement over placebo.…”

“…45,49,55,58 There is con¯icting evidence as to whether tamsulosin 0.4 and 0.8 mg produce different magnitudes of symptom relief. While the 0.4 mg dose produced a 9 ± 14% improvement over placebo in symptom score in four studies, 45,46,49,55 in one study the 0.8 mg produced a 20% improvement over placebo. 55 The recent Narayan study, however, suggests that there is no difference between the two dose levels in relieving symptoms.…”

“…Some trials de®ned response as a ! 25% improvement in symptom score from baseline, 45,49,55,58 while others used more stringent thresholds of ! 30%, 51,56 !…”

“…46 Also, there is a marked difference in the incidence of side effects reported in the two US tamsulosin trials 55,58 vs the three European tamsulosin trials. 45,46,49 It is uncertain whether this is due to cultural differences, to the methodologies of the reporting of side effects, or to other factors.…”